reported that both of vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) increased in tumor and suppressed the immune microenvironment, lenvatinib can reduce the level of these two cytokines to improve the efficacy of PD-1 (41). Here, VEGFA is linked to neoplasm.